RZLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rezolute Inc. (RZLT) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has significant negative catalysts, weak technical indicators, and no strong positive momentum or signals to justify an entry at this time.
The technical indicators for RZLT are bearish. The MACD histogram is negative and expanding, the RSI is neutral at 38.2, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 3.003, with resistance at 3.568. Overall, the trend does not suggest a strong buying opportunity.
There are no strong positive catalysts. Analysts note potential value in the company's ongoing open-label Phase 3 upLIFT study in tumor hyperinsulinism, but this is speculative and contingent on future developments.
The company recently faced a significant setback with the failure of its Phase 3 sunRIZE trial, leading to a sharp drop in share price (85-90%). Legal investigations into investor losses are ongoing, and analysts have significantly lowered price targets. Trading sentiment is weak, with hedge funds and insiders showing neutral activity.
In Q2 2026, the company reported no revenue growth (0.00% YoY), a net income loss of -$22.77M (improved by 44.78% YoY), and an EPS of -0.22 (unchanged YoY). Gross margin remains at 0%. The financials indicate no significant growth or profitability, which is a concern for long-term investors.
Analyst sentiment is mixed to negative. While some analysts maintain a Buy rating, most have significantly lowered price targets, citing the failure of the sunRIZE trial and reduced growth prospects. Wedbush downgraded the stock to Neutral with a price target of $1, and other firms have similarly reduced their targets, reflecting skepticism about the company's future prospects.
